» Articles » PMID: 19404953

Premature Atherosclerosis in Pediatric Systemic Lupus Erythematosus: Risk Factors for Increased Carotid Intima-media Thickness in the Atherosclerosis Prevention in Pediatric Lupus Erythematosus Cohort

Abstract

Objective: To evaluate risk factors for subclinical atherosclerosis in a population of patients with pediatric systemic lupus erythematosus (SLE).

Methods: In a prospective multicenter study, a cohort of 221 patients underwent baseline measurements of carotid intima-media thickness (CIMT) as part of the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) trial. SLE disease measures, medications, and traditional risk factors for atherosclerosis were assessed. A standardized protocol was used to assess the thickness of the bilateral common carotid arteries and the mean maximal IMT of 12 segments. Univariable analysis identified potential associations with CIMT, which were examined in multivariable linear regression modeling.

Results: Based on the mean-mean common or the mean-max CIMT as the dependent variable, univariable analysis showed significant associations of the following variables with increased CIMT: increasing age, longer SLE duration, minority status, higher body mass index (BMI), male sex, increased creatinine clearance, higher lipoprotein(a) level, proteinuria, azathioprine treatment, and prednisone dose. In multivariable modeling, both azathioprine use (P=0.005 for the mean-mean model and P=0.102 for the mean-max model) and male sex (P<0.001) were associated with increases in the mean-max CIMT. A moderate dosage of prednisone (0.15-0.4 mg/kg/day) was associated with decreases in the mean-max CIMT (P=0.024), while high-dose and low-dose prednisone were associated with increases in the mean-mean common CIMT (P=0.021) and the mean-max CIMT (P=0.064), respectively. BMI (P<0.001) and creatinine clearance (P=0.031) remained associated with increased mean-mean common CIMT, while increasing age (P<0.001) and increasing lipoprotein(a) level (P=0.005) were associated with increased mean-max CIMT.

Conclusion: Traditional as well as nontraditional risk factors were associated with increased CIMT in this cohort of patients in the APPLE trial. Azathioprine treatment was associated with increased CIMT. The relationship between CIMT and prednisone dose may not be linear.

Citing Articles

Investigation of the performance of validated cardiovascular risk scores in a global (UK/US) cohort of young people with childhood-onset systemic lupus erythematosus.

Ciurtin C, Peng J, Gao Y, Niwa M, Ardoin S, Schanberg L Lupus Sci Med. 2024; 11(1).

PMID: 38871459 PMC: 11177662. DOI: 10.1136/lupus-2024-001194.


Assessment of Arterial Stiffness and Biochemical Markers in Systemic Lupus Erythematosus in the Diagnosis of Subclinical Atherosclerosis.

Blachut D, Przywara-Chowaniec B, Mazurkiewicz M, Tomasik A J Pers Med. 2024; 14(3).

PMID: 38541031 PMC: 10971100. DOI: 10.3390/jpm14030289.


Systemic lupus erythematosus patients have unique changes in serum metabolic profiles across age associated with cardiometabolic risk.

Jury E, Peng J, Van Vijfeijken A, Martin Gutierrez L, Woodridge L, Wincup C Rheumatology (Oxford). 2023; 63(10):2741-2753.

PMID: 38048621 PMC: 11443078. DOI: 10.1093/rheumatology/kead646.


Atherosclerosis Progression in the APPLE Trial Can Be Predicted in Young People With Juvenile-Onset Systemic Lupus Erythematosus Using a Novel Lipid Metabolomic Signature.

Peng J, Donnes P, Ardoin S, Schanberg L, Lewandowski L, Robinson G Arthritis Rheumatol. 2023; 76(3):455-468.

PMID: 37786302 PMC: 10922368. DOI: 10.1002/art.42722.


Childhood rheumatic diseases: bites not only the joint, but also the heart.

Thomas K, Aggarwal A Clin Rheumatol. 2023; 42(10):2703-2715.

PMID: 37160484 PMC: 10169151. DOI: 10.1007/s10067-023-06621-9.


References
1.
Bots M, Evans G, Riley W, Grobbee D . Carotid intima-media thickness measurements in intervention studies: design options, progression rates, and sample size considerations: a point of view. Stroke. 2003; 34(12):2985-94. DOI: 10.1161/01.STR.0000102044.27905.B5. View

2.
Bots M, Evans G, Riley W, Meijer R, McBride K, Paskett E . The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study: design and baseline characteristics. Control Clin Trials. 2003; 24(6):752-75. DOI: 10.1016/s0197-2456(03)00096-5. View

3.
Crouse 3rd J, Raichlen J, Riley W, Evans G, Palmer M, OLeary D . Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007; 297(12):1344-53. DOI: 10.1001/jama.297.12.1344. View

4.
Stone N . Secondary causes of hyperlipidemia. Med Clin North Am. 1994; 78(1):117-41. DOI: 10.1016/s0025-7125(16)30179-1. View

5.
Espeland M, Tang R, Terry J, Davis D, Mercuri M, Crouse 3rd J . Associations of risk factors with segment-specific intimal-medial thickness of the extracranial carotid artery. Stroke. 1999; 30(5):1047-55. DOI: 10.1161/01.str.30.5.1047. View